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Abstract 
 
Background: It is more than sixty years that the concept of the fetal allograft and 
immunological paradox of pregnancy was proposed and in this context, several regu-
latory networks and mechanisms have been introduced so far. It is now generally rec-
ognized that mesenchymal stem cells exert potent immunoregulatory activity. In this 
study, for the first time, the potential impact of Menstrual blood Stem Cells (MenSCs), 
as surrogate for endometrial stem cells, on proliferative capacity of CD4+ T cells was 
tested.  
 
Methods: MenSCs and Bone marrow Mesenchymal Stem Cells (BMSCs) were isolated 
and assessed for their immunophenotypic features and multi-lineage differentiation 
capability. BMSCs and MenSCs with or without IFNγ pre-stimulation were co-cultured 
with purified anti-CD3/CD28-activated CD4+ T cells and the extent of T cell prolifera-
tion at different MenSCs: T cell ratios were investigated by CSFE flow cytometry. IDO 
activity of both cell types was measured after stimulation with IFNγ by a colorimetric 
assay.   
 
Results: MenSCs exhibited dual mesenchymal and embryonic markers and multi-
lineage differentiation capacity. MenSCs significantly increased proliferation of CD4+ 
cells at ratios 1:2, 1:4 and 1:8. IFNγ pre-treated BMSCs but not MenSCs significantly sup-
pressed CD4+ T cells proliferation. Such proliferation promoting capacity of MenSCs 
was not correlated with IDO activity as these cells showed the high IDO activity fol-
lowing IFNγ treatment.   
 
Conclusion: Although augmentation of T cell proliferation by MenSCs can be a basis 
for maintenance of endometrial homeostasis to cope with ascending infections, this 
may not fulfill the requirement for immunological tolerance to a semi-allogeneic fe-
tus. However, more investigation is needed to examine whether or not the immuno-
modulatory properties of these cells are affected by endometrial microenvironment 
during pregnancy. 
 
 
Keywords: Endometrium, Immunological tolerance, Menstrual blood stem cells, Pregnancy, 
Proliferation, T lymphocytes  
 
 
 
Introduction 
 
One of the most controversial issues in reproductive 
biology is dealing with the fact that a fully functional 
immune system in women should simultaneously fight 
off the invading pathogens and tolerate semi-allograft 
fetus throughout the pregnancy. Indeed, a successful  
 
 
 
 
 
pregnancy is supposed to remain unresponsive to pa-
ternal antigens originating from semi-allograft fetus.  
Thus far, extensive attempts and studies have been 
performed to unravel immunosuppressive mechanisms 
involved in immunological tolerance of gestation. En-
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dometrium undergoes immunological changes to estab-
lish tolerance during the onset of pregnancy. Along 
with gestation initiation, such immune cells as Natural 
Killer cells (NKs), monocytes, Dendritic Cells (DCs) 
and T cells are recruited to the endometrium. The phe-
notype of decidual immune cells changes in a way to 
cooperate with tolerance. Recruited NK cells, for in-
stance, transform into decidual NK cells (dNK) with a 
reduced cytotoxic and augmented secretary activity 1-3. 
Macrophage and NK cells together induce tolerogenic 
DCs (tDCs) 4, which per se promote Treg differentia-
tion. Nevertheless, it has been reported that depleting 
Tregs causes only a 10% fetal loss in the first pregnan-
cy of mice 5. Indeed, there is evidence that Fas (First 
apoptosis signal), Indoleamine 2,3-dioxygenase (IDO) 
and Programmed Death-Ligand 1 (PD-L1) suppress 
fetus antigen-specific effector T cells 6-8, but immuno-
tolerance is not interrupted even if one of these factors 
is absent in allogeneic matings in Ido1−/− or Fasl−/− 
mice 6,9. Although redundancy and overlapping com-
pensatory mechanisms may explain in part the afore-
said phenomenon, one tempting hypothesis would be 
immunomodulation at the feto-maternal interface by 
non-immune cells residing in the endometrium.     
Immunomodulatory functions are not limited to im-
mune cells. Numerous researches have addressed im-
munomodulation as the prominent feature of Mesen-
chymal Stem Cells (MSCs). Plenty of studies have 
shown that MSCs derived from a variety of tissues 
such as bone marrow, adipose and amniotic membrane 
have immunomodulatory properties exemplified by 
suppressing T cell activation and proliferation 10-14.  
In 2004, the existence of a specific population of 
cells in the endometrium with ability to form Colony 
Forming Unit (CFU) was introduced 15,16. Subsequent-
ly, it was reported that CD146+ colonogenic human 
perivascular endometrial stromal cells might be poten-
tial stromal stem/progenitor cells 17. Complementary 
information was provided by Gargett et al who showed 
that endometrial colonogenic stromal cells possess all 
criteria that a cell needs to be categorized as MSCs 18. 
Based on non-invasive method of collection, menstrual 
blood as a source for a MSCs originated from endome-
trium was then extensively investigated. It was ob-
served that menstrual blood-derived stem cells con-
tained heterogeneous cell populations, expressed MSCs 
markers and were able to differentiate into chondro-
genic, adipogenic, and osteogenic cell lineages 19. In 
addition, they observed a similarity between endome-
trial and Menstrual Blood Stem Cells (MenSCs) with 
respect to the expression of c-Kit 20 and Oct-4 21; they 
concluded that MenSCs are possibly endometrium 
MSCs shed during menstruation 19.  
Although more than a decade since the first intro-
duction of endometrial stem cells in general and the 
menstrual blood stem cells, in particular, have passed, 
there is very limited data on their potential immuno-
regulatory capacity. Previously, our group demonstrat-
ed that MenSCs dampen allogeneic MLR 22 and inter-
fere with the process of DC differentiation and matura-
tion 23.  
Given the presence of T cells in endometrium and 
their pivotal role in maintenance of successful preg-
nancy and also in pregnancy related complications such 
as abortion, in this study, an attempt was made to ex-
plore how endometrial mesenchymal stromal cells con-
trol CD4+ T cells responses. 
 
Materials and Methods 
 
MenSCs and BMSCs collections 
MenSCs were obtained from 10 apparently healthy 
women (25-35 years). The women were monitored to 
exclude those with a history of vaginal infection or 
consumption of oral contraceptives, corticosteroids and 
Nonsteroidal Anti-inflammatory Drug (NSAIDs) dur-
ing the last 3 months, endometriosis, autoimmune dis-
eases and infection with such blood transmittable vi-
ruses such as HCV, HBV and HIV. A written consent 
was obtained from all donors before enrolment to the 
study. BMSCs were from four healthy donors admitted 
for bone marrow transplantation and provided by Re-
productive Biotechnology Research Center, Avicenna 
Research Institute, Tehran, Iran. MenSCs were collect-
ed on the 2nd day of menstruation phase using menstru-
al cup. Samples were transferred to the lab in a transfer 
medium comprising DMEM/F12, 100 µg/ml penicillin, 
100 IU/ml streptomycin and 0.25 µg/ml fungizone (In-
vitrogen, Carlsbad, CA). Clots and tissue derbies were 
separated using cell strainer with 70 µm pore size. 
Then, menstrual blood was cultured in DMEM/F12 
media supplemented with 10% Fetal Bovine Serum 
(FBS) (Invitrogen, Carlsbad, CA) and with the same 
concentration of antibiotics as mentioned above. Every 
two or three days, media were replenished, suspended 
cells were removed and the adherent cells were pas-
saged up to 5 times. These cells were considered as 
MenSCs and frozen for the following experiments.  
 
Immunophenotyping 
MenSCs and BMSCs were harvested after two pas-
sages and evaluated for their immunophenotype char-
acteristics using antibodies against MSCs markers: CD9, 
CD10, CD44, CD73 and CD105, embryonic stem cells 
markers; Oct-4, Nanog, Stro-1 and SSEA-4 and hema-
topoietic markers; CD34, CD38, CD45, and CD133. The 
specification of antibodies is summarized in table 1. 
 
Multi-lineage differentiation 
MenSCs and BMSCs were differentiated into adipo-
genic, chondrogenic and osteogenic lineages using spe-
cific polarizing media as per method described previ-
ously 24,25. In brief, MenSCs and BMSCs were seeded 
in 24-well plates at 5×104 cell/well. For adipogenic 
differentiation, MenSCs or BMSCs were cultured in 
DMEM-F12/FBS 10% supplemented with 1 µM rosig-
litazone (St Louis, MO, USA), 10 µg/ml human re-
combinant insulin, 0.5 mM IBMX (3-Isobutyl-1-me-
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thylxanthine) (St Louis, MO, USA) and 1 µM dexame-
thasone (Cosar Pharmaceutical Company). Chondro-
genic differentiation medium was made of DMEM-
F12/FBS 10% comprising 100 µg/ml sodium pyruvate 
(Invitrogen, Carlsbad, CA), 20 ng/ml TGF-β3 (St Lou-
is, MO, USA), 100 nM dexamethasone, ITS+1 1X (St 
Louis, MO, USA), 50 µg/ml ascorbic acid (St Louis, 
MO, USA) and 2% FBS. To differentiate into osteo-
genic lineage, culture media contained complete high 
glucose DMEM supplemented with 0.1 µM dexame-
thasone, 50 µM ascorbic acid and 10 µM β-glycero-
phosphate (Sigma, St Louis, MO, USA). As control 
wells, the same cell number was seeded in the same 
plates without any polarizing agents. To evaluate dif-
ferentiation into adipogenic, chondrogenic and osteo-
genic lineages, Oil red, Alcian blue and Alizarin red 
staining was employed, respectively.  
 
T cell isolation and co-culture 
Peripheral blood samples were obtained from healthy 
donors. Then Peripheral Blood Mononuclear Cells 
(PBMCs) were isolated using density gradient Ficoll 
paque medium (Amersham, UK). CD4+ T cells were 
purified from PBMCs using magnetic beads negative 
selection kit (Miltenyi Biotec, Germany) with approx-
imate purity of 95%. CD4+ T cells were co-cultured (at 
4×105 cells/well) with MenSCs at 1:2 to 1:128 ratios 
(MenSCs: CD4+ T cells) in 24-well plates for five 
days. During culture, CD4+ T cells were stimulated 
with anti-CD3 and anti-CD28-loaded activation beads 
at a ratio of 1:4 (bead:cell) (Miltenyi Biotec, Germa-
ny). 
 
Pre-treatment of MenSCs with IFNγ  
In some settings, MenSCs and BMSCs were stimu-
lated with 25 ng/ml IFNγ in 24-well plates for 48 hr 
before co-culture with CD+ T cells. Thereafter, Men-
SCs and BMSCs were co-cultured for five days with 
CD4+ T cells as above, at ratios of (MSCs: CD4+ T 
cells) 1:4-1:8 and 1:5, respectively.   
 
Proliferation assay 
The modulatory action of MSCs on T cells prolifer-
ation was investigated by CFSE flow cytometry. To 
this end, CFSE-labeled (Molecular probe, USA) CD4+ 
T cells were cultured in the presence or absence of 
MSCs for five days, harvested and analyzed using flow 
cytometry (Attune NXT, Thermo Fisher, Carlsbad, 
USA). For CFSE labeling, CD4+ T cells were stained 
with 5 µM CFSE dye solution and washed two times 
prior to co-culture with MSCs.   
 
IDO activity assay 
IDO activity in MenSCs and BMSCs supernatant 
was assessed with or without IFNγ pre-stimulation.  
MenSCs or BMSCs were seeded at 1×105 cell/well in 
650 µL DMEM-F12/FBS 10% (24-well plate). To 
evaluate IDO activity, 100 µg/ml tryptophan (Sigma, St 
Louis, MO, USA) was added to each well in the pres-
ence or absence of 100 ng/ml IFNγ (control wells con-
tained only culture media) and incubated in a humidi-
fied incubator for 48 hr. Supernatant was harvested and 
prepared as described elsewhere 26. IDO activity was 
then assessed through measurement of tryptophan cata-
bolite (kynurenine) concentration, using a plate reader 
(Biotec, VT, USA) at 450 nm.  
 
Statistical analysis 
Flow cytometry data were analyzed using Flowjo 
7.6.1 Software (Tree Star Inc., Ashland, USA). All 
colorimetric experiments were performed in triplicate. 
Mann-Whitney was used to evaluate the differences. 
All graphs are displayed using median and rage. P val-
ues less than 0.05 were considered statistically signifi-
cant. The analysis was done using Prism software 6.0 
(GraphPad Software Inc., San Diego, USA).  
 
Results 
 
MenSCs exhibited dual mesenchymal and embryonic mark-
ers and multi-lineage differentiation capacity  
MenSCs and BMSCs expressed MSCs markers in-
cluding CD9, CD10, CD29, CD44, CD73 and CD105, 
they were also negative for hematopoietic markers, 
CD34, CD38, CD45 and CD133. MenSCs also ex-
pressed Oct-4 but failed to express SSEA-4, while the 
opposite pattern was the case for BMSCs (Figure 1), 
(Table 2). Both MenSCs and BMSCs were capable of 
differentiating into adipogenic, chondrogenic and osteo-
genic lineages confirming their MSCs identity. Men-
SCs showed less potency to differentiate into osteo-
genic and adipogenic lineages compared to BMSCs 
(Figure 2). 
 
MenSCs augmented CD4+ T cells proliferation 
To assess the immunomodulatory capability of Men-
SCs, they were co-cultured with CFSE-labeled anti-
CD3/anti-CD28-activated CD4+ T cells at different rati-
os. As shown in figure 3, MenSCs significantly in-
creased proliferation of CD4+ cells at ratios 1:2, 1:4 
and 1:8 (p<0.001). Although the rate of proliferation at 
higher ratios was higher compared to the CD4+ T cells 
Table 1. Antibody panel for immunophenotyping 
 
Antibody Fluorochrome Clone Company 
Anti-CD9 FITC M-L13 BD Bioscience 
Anti-CD10 PE HI10a BD Bioscience 
Anti-CD29 PE MAR4 BD Bioscience 
Anti-CD34 FITC 581 BD Bioscience 
Anti-CD38 FITC HIT2 BD Bioscience 
Anti-CD44 PE 515 BD Bioscience 
Anti-CD45 PE HI30 BD Bioscience 
Anti-CD73 PE AD2 BD Bioscience 
Anti-CD105 PE 166707 R&D systems 
Anti-CD133 PE W6B3C1 BD Bioscience 
Anti-Nanog - Polyclonal Abcam 
Anti-Oct-4 - Polyclonal Abcam 
Anti-SSEA-4 - MC813-70 BD Bioscience 
Anti-Stro-1 - STRO-1 R&D systems 
Anti-rabbit Ig FITC Polyclonal Abcam 
Anti-mouse IgG FITC Polyclonal Sina Biotech 
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cultured alone, the differences were not reached to the 
statistically significant level. 
 
IFNγ pre-treated BMSCs but not MenSCs suppressed CD4+ 
T cells proliferation 
BMSCs as the most studied source of MSCs with 
potent immunomodulatory impact on T cell prolifera-
tion upon stimulation with pro-inflammatory cytokines 
such as IFNγ, IL-1β and TNF-α were tested as positive 
control. IFNγ pre-stimulated BMSCs significantly sup-
pressed proliferation of CD4+ T cells compared to the 
control wells (p<0.05). Although CD4+ T cells prolif-
eration was reduced in the presence of IFNγ pre-stimu-
Figure 1. Immunophenotyping of MenSCs and BMSCs. MenSCs and BMSCs were evaluated for the expression of MSCs markers, CD9, CD10, CD29, 
CD44, CD73 and CD105, hematopoietic makers, CD34, CD38, CD45 and CD133, and pluripotency makers, Nanog, Oct-4, SSEA-4 and Stro-1. The 
grey and empty histograms represent unstained sample and test samples, respectively. Results are representative of three individual experiments. 
Table 2. Expression of mesenchymal and embryonic stem cell 
markers by MenSCs and BMSCs 
 
Markers MenSCs BMSCs 
CD34 1.7±0.9% 0.92±0.4% 
CD38 1.4±0.7% 1.9±1.3% 
CD45 1.1±0.7% 1.7±0.8% 
CD133 1.9±0.7% 2.1±1.6% 
CD9 90.8±6.7% 92.1±5% 
CD10 89.4±5.7% 40.1±18% 
CD29 98.7±1.26% 94.9±5% 
CD44 99±0.2% 96.97±3% 
CD73 99.7±0.2% 97.6±1.2% 
CD105 89.6±9.6% 99.7±0% 
Stro-1 4.7±1.4% 8.7±3.4% 
Oct-4 99.5±0% 1.4±1.1% 
Nanog 2.5±0.4% 7±2.4% 
SSEA-4 1.8±0.8% 78.3±11.4% 
 
 
Figure 2. Multi-lineage differentiation potential of MenSCs and 
BMSCs. The left and right pictures of each panel represent differen-
tiated (Dif) and undifferentiated (Undif) stem cells, respectively. 
Differentiation of stem cells toward osteocytes, chondrocytes and 
adipocytes were assessed by Alizarin red, Alcian blue and Oil red 
staining, respectively. Results are representative of three individual 
experiments. 
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lated MenSCs (p<0.05), it was still significantly higher 
than the control (p<0.0001) (Figure 4). 
 
IFNγ induced IDO activity in both MenSCs and BMSCs  
IDO has been widely studied due to its role in toler-
ance. IFNγ is the most potent stimulator of IDO activi-
ty. In this context, MenSCs and BMSCs were stimulat-
ed with IFNγ and IDO activity was measured in cell 
culture supernatant. Our results showed that in Men-
SCs, IDO activity was induced in both cell types after 
stimulation with IFNγ compared to the un-treated cells. 
Both MenSCs and BMSCs exhibited higher IDO activ-
ity compared with controls, after stimulation with IFNγ 
(p<0.0001) (Figure 5).  
 
Discussion 
 
Although plenty of mechanisms and regulatory net-
works for establishment of immune tolerance at the 
feto-maternal interface have been introduced, the po-
tential immunomodulatory role of endometrial stromal 
stem cell has been largely ignored. During the past 
couple of years, the immunomodulatory properties of 
mesenchymal stem cells have attracted interest of many 
researchers and to a large extend have foregrounded 
the principal application of this cell population in re-
generative medicine. In this study, the potential im-
munomodulatory impact of MenSCs, as surrogate cells 
for endometrial mesenchymal stem cells, on T cell pro-
liferation was addressed. As with previous reports 25, it 
was shown that MenSCs possessed minimal criteria 
necessary for defining a cell type as MSCs exemplified 
by the expression of markers associated with mesen-
chymal origin and multi-lineage differentiation 25. Ex-
pression of the embryonic marker, Oct-4, by MenSCs 
is a further support to the previous reports on higher 
proliferation capacity of these cells compared to BMSCs 
27.   
In the next step, the potential modulatory effect of 
MenSCs on CD4+ T cells proliferation was examined 
in reference to BMSCs. It was shown that at MenSCs: 
T cell ratios of 1:2-1:8, MenSCs supported CD4+ T 
cells proliferation. This finding seems to have contra-
diction with our previous results 22, because in that 
report MenSCs were able to suppress allogenic MLR at 
1:1 and 1:2 (MenSCs: PBMCs) ratios. Notably, in al-
logeneic MLR, a mixture of pro-inflammatory cyto-
kines profiles is produced by responder cells including 
IL-1β and TNF-α 28 which are able to induce anti-
inflammatory phenotype in MSCs 29. Hence, it could 
be inferred that inflammatory milieu during MLR reac-
tion may help to boost MSCs immunomodulatory ca-
pabilities. On the other hand, MSCs use monocyte-
dependent mechanism to halt T cell responses 30-32 
which was absent in the system reported here. Alt-
hough by taking our initial concept into consideration, 
this finding was out of our expectation, the following 
explanation could be put forth. The upper part of 
Figure 3. Effect of MenSCs on proliferation of CD4+ T cells. A) MenSCs were co-cultured at different ratios with anti-CD3/CD28-activated purified 
CD4+ T cells for 5 days and the percent of proliferation was assessed by CFSE flow cytometry. B) Representative histogram plots are shown.  The 
grey and empty histograms represent test samples (co-culture) and biological controls (BC) (CD4+ T cells cultured alone), respectively. Results are 
representative of nine individual experiments. ***: p<0.001. 
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female reproductive tract is sterile and in non-pregnant 
women, immune system needs to be on a stand-by 
mode to properly respond to any invading pathogen; 
hence, it seems logical to assume that every potential 
immunotolerance mechanism remains at low functional 
level during non-pregnant state 33. Dual  anti-inflam-
matory or pro-inflammatory phenotype of MSCs de-
pending upon microenvironment milieu has already 
been reported 34.  
The onset of pregnancy and blastocyst implantation 
is associated with inflammatory processes initiated by 
insemination 35 and recruitment of dNK cells. Besides 
endometrial immune cells such as dNK cells which 
produce IFNγ 36,37, endometrial non-immune cells are 
also a potential source for establishment of inflamma-
tory milieu 38. Interestingly, most MSCs acquire anti-
inflammatory phenotype upon treatment with such pro-
inflammatory cytokines as IFNγ 39-41. With this in 
mind, effect of IFNγ pre-treatment on modulatory ac-
tivity of MenSCs on the proliferative response of CD+ 
T cells was evaluated in the next step.    
As expected, IFNγ-treated BMSCs significantly in-
hibited T cell proliferation, which was in accordance 
with results reported by other groups 10,42,43. Although 
IFNγ treatment of MenSCs reduced their capacity to 
augment T cell proliferation, it was still significantly 
higher than control. This finding may be due to the 
lower expression level of IFNγ receptor in MenSCs 
compared with BMSCs 44. Almost a similar result was 
observed in umbilical cord-derived MSCs co-cultured 
with PHA-activated PBMCs 45. On the other hand, in-
duction of IDO activity in MenSCs treated with IFNγ 
implies that suppressive activity of MenSCs IDO on T 
cell proliferation was not sufficient enough to over-
come yet undetermined proliferation supportive mech-
anisms of this cell population.   
Figure 4. Effect of IFNγ stimulation of MenSCs on proliferation of CD4+ T cells: A) MenSCs were co-cultured with CD4+ T cells at 1:4 and 1:8 
(MenSCs:CD4+ T cells) ratios with or without IFNγ pre-stimulation for five days and the percent of proliferation was assessed by CFSE flow 
cytometry. B) IFNγ pre-stimulated BMSCs were used as positive control in CD4+ T cells proliferation assay. Figures on the right in each panel rep-
resent histogram plots of corresponding proliferation assays. The empty histograms represent biological controls (BC) (CD4+ T cells cultured alone) 
and grey histograms represent test samples (co-culture). Results are representative of ten individual experiments *: p<0.05 and ****: p<0.0001.  
 
Figure 5. Assessment of IDO activity in MenSC and BMSC super-
natants after stimulation with IFNγ. IDO activity was measured 
using kynurenine colorimetric assay. The results are median and 
rage of four BMSCs and six MenSCs samples ****: p<0.0001.  
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It is notable that, IFNγ is not the only pro-inflam-
matory cytokine in early pregnancy decidua. Expres-
sion of other pro-inflammatory cytokines including IL-
1, TNF-α, and IL-18 in early pregnancy decidua is up-
regulated 46. Interestingly, IL-1β and TNF-α are among 
the pro-inflammatory cytokines that have been proven 
to induce anti-inflammatory phenotype in MSCs 47-51. 
Thus, it remains to be investigated whether endometrial 
microenvironment during pregnancy can affect the 
immunomodulatory properties of MenSCs.   
 
Conclusion 
Our results showed that MenSCs induce prolifera-
tion of CD4+ T cells which could be a basis for main-
tenance of endometrial homeostasis to cope with as-
cending infections. This feature, however, seems to be 
contradictory to the requirement for immunological 
tolerance to semi-allogeneic fetus. Whether or not this 
immune enhancement capacity of MenSCs is modulat-
ed during pregnancy under the influence of immuno-
suppressive hormones and mediators needs to be de-
termined.   
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